Interview with Jane Provis Evans, Head cGMP services at Nanopharm
In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.
Dry Powder Inhaler Formulations: Microstructural Analysis Techniques
The paper titled “Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques” explores the use of advanced analytical methods to improve our understanding of the performance of dry powder inhalers (DPIs).
Exploring PBPK Modeling in Nasal Drug Delivery: Expert Insights from Will Ganley
Explore PBPK modeling for OINDP and nasal drug delivery, optimizing drug development and reducing clinical trial needs
Driving Innovation in Inhaled and Nasal Drug Product Development
Explore how Nanopharm, a globally recognized Contract Research Organization (CRO), is becoming the inevitable choice for inhalation and nasal drug product development. Under the leadership of Gemma Budd, the new General Manager, Nanopharm has established itself as a Centre of Excellence in Orally Inhaled and Nasal Drug Products (OINDP). With its state-of-the-art, purpose-built facility, Nanopharm offers comprehensive inhalation services, characterized by an in-depth understanding of OINDP science, products, and test methods.
Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Intranasal Drug Delivery: Unravelling the Nanoparticle Formulation Puzzle
Navigate the complexities of formulating nanoparticles for intranasal drug delivery with expert insights
Dual Excipient Integration in Dry Powder Inhaler Products
Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.
Propellant Aerosols & Transition to Low GWP pMDIs
Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.
Primary Crystallization’s Influence on Fluticasone DPIs
Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.
